• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma.

作者信息

Chen Lucia Y, Thibaud Santiago, Bodnar Saoirse, Chari Ajai, Richter Joshua, Cho Hearn Jay, Sanchez Larysa J, Rodriguez Cesar, Rossi Adriana C, Richard Shambavi, Parekh Samir, Jagannath Sundar

机构信息

Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, United Kingdom.

Division of Hematology/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

出版信息

Blood Adv. 2025 Jan 14;9(1):176-179. doi: 10.1182/bloodadvances.2024014097.

DOI:10.1182/bloodadvances.2024014097
PMID:39546749
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11788124/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3ef/11788124/5e0df5521a11/BLOODA_ADV-2024-014097-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3ef/11788124/5e0df5521a11/BLOODA_ADV-2024-014097-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3ef/11788124/5e0df5521a11/BLOODA_ADV-2024-014097-gr1.jpg

相似文献

1
MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma.最新一线治疗后的微小残留病阴性持续时间可预测真实世界中多发性骨髓瘤患者的长期无进展生存期。
Blood Adv. 2025 Jan 14;9(1):176-179. doi: 10.1182/bloodadvances.2024014097.
2
Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis.抗CD38单克隆抗体疗法与标准疗法在新诊断的多发性骨髓瘤患者中的疗效和安全性：一项系统评价和荟萃分析
Ther Adv Hematol. 2025 Jan 27;16:20406207251314289. doi: 10.1177/20406207251314289. eCollection 2025.
3
The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice.Euroflow微小残留病评估在真实世界多发性骨髓瘤实践中的效用
Front Oncol. 2022 May 18;12:820605. doi: 10.3389/fonc.2022.820605. eCollection 2022.
4
Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry.使用流式细胞术评估微小残留病（MRD）对多发性骨髓瘤预后价值的真实世界证据。
Eur J Haematol. 2025 Jan;114(1):155-163. doi: 10.1111/ejh.14316. Epub 2024 Oct 10.
5
Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil.来那度胺维持治疗与巴西接受不同治疗策略的真实世界多发性骨髓瘤移植人群中的可测量残留病：以获得新型药物为导向
Cancers (Basel). 2023 Mar 4;15(5):1605. doi: 10.3390/cancers15051605.
6
[Impact of minimal residual disease detection after treatment of multiple myeloma].[多发性骨髓瘤治疗后微小残留病检测的影响]
Orv Hetil. 2019 Mar;160(13):502-508. doi: 10.1556/650.2019.31353.
7
Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.双打击多发性骨髓瘤高危患者自体干细胞移植后 MRD 阴性的真实世界优势和挑战。
BMC Cancer. 2024 Apr 2;24(1):406. doi: 10.1186/s12885-024-12077-0.
8
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.自体造血细胞移植及来那度胺维持治疗 1 年后多发性骨髓瘤微小残留病灶状态与长期总生存相关。
J Clin Oncol. 2024 Aug 10;42(23):2757-2768. doi: 10.1200/JCO.23.00934. Epub 2024 May 3.
9
Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.微小残留病灶状态是接受高剂量治疗的多发性骨髓瘤患者的预后决定因素。
Cancer Med. 2023 Nov;12(22):20736-20744. doi: 10.1002/cam4.6640. Epub 2023 Nov 3.
10
[The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].[初诊多发性骨髓瘤患者微小残留病（MRD）状态动态监测的预后意义]
Zhonghua Xue Ye Xue Za Zhi. 2019 Jul 14;40(7):584-588. doi: 10.3760/cma.j.issn.0253-2727.2019.07.009.

引用本文的文献

1
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.西达基奥仑赛治疗复发/难治性多发性骨髓瘤的CARTITUDE-1患者后的长期（≥5年）缓解和生存情况
J Clin Oncol. 2025 Sep;43(25):2766-2771. doi: 10.1200/JCO-25-00760. Epub 2025 Jun 3.

本文引用的文献

1
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.来那度胺和地塞米松维持治疗联合或不联合伊沙佐米，根据骨髓瘤患者的残留疾病状态进行调整。
Blood. 2023 Nov 2;142(18):1518-1528. doi: 10.1182/blood.2022019531.
2
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials.TOURMALINE-MM3 和-MM4 试验中 1280 例骨髓瘤患者维持治疗期间微小残留病灶动态变化与预后改善的关系。
Blood. 2023 Feb 9;141(6):579-591. doi: 10.1182/blood.2022016782.
3
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
自体干细胞移植后多发性骨髓瘤患者的微小残留病：预后意义和来那度胺维持治疗及分子风险的影响。
J Clin Oncol. 2022 Sep 1;40(25):2889-2900. doi: 10.1200/JCO.21.02228. Epub 2022 Apr 4.
4
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma.多发性骨髓瘤骨髓微小残留病灶阴性丢失的临床意义。
Blood Adv. 2022 Feb 8;6(3):808-817. doi: 10.1182/bloodadvances.2021005822.
5
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.骨髓瘤中微小残留病阴性的预后价值：POLLUX、CASTOR、ALCYONE和MAIA的联合分析
Blood. 2022 Feb 10;139(6):835-844. doi: 10.1182/blood.2021011101.
6
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.新诊断多发性骨髓瘤中持续的微小残留病灶阴性和达雷妥尤单抗在 MAIA 和 ALCYONE 中的作用。
Blood. 2022 Jan 27;139(4):492-501. doi: 10.1182/blood.2020010439.
7
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.深度测序检测微小残留病灶阴性是多发性骨髓瘤的一个主要预后因素。
Blood. 2018 Dec 6;132(23):2456-2464. doi: 10.1182/blood-2018-06-858613. Epub 2018 Sep 24.
8
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.微小残留病与多发性骨髓瘤患者更好的生存结果的关联：一项荟萃分析。
JAMA Oncol. 2017 Jan 1;3(1):28-35. doi: 10.1001/jamaoncol.2016.3160.
9
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
10
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.多参数流式细胞术检测多发性骨髓瘤微小残留病：对 MRC 骨髓瘤 IX 研究结果的影响。
J Clin Oncol. 2013 Jul 10;31(20):2540-7. doi: 10.1200/JCO.2012.46.2119. Epub 2013 Jun 3.